Evidence map›Paper›PMID 31930750›Full record

ArticleXenotransplantation2020

Viral opportunistic infections in Mauritian cynomolgus macaques undergoing allogeneic stem cell transplantation mirror human transplant infectious disease complications.

Helen L Wu, Whitney C Weber, Christine Shriver-Munsch, Tonya Swanson, Mina Northrup, Heidi Price, Kimberly Armantrout, Mitchell Robertson-LeVay, Jason S Reed, Katherine B Bateman and 19 more

Open access · greenAbstract read
In one paragraph

Article in Xenotransplantation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 2 institutions in 1 country.

Helen L WuVaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon.ORCID 0000-0001-7101-5160
Whitney C WeberVaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon.
Christine Shriver-MunschOregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon.
Tonya SwansonOregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon.
Mina NorthrupVaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon.
Heidi PriceOregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon.
Kimberly ArmantroutOregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon.
Mitchell Robertson-LeVayOregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon.
Jason S ReedVaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon.
Katherine B BatemanVaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon.
Eisa MahyariOregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon.
Archana ThomasOregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon.
Stephanie L JunellDepartment of Radiation Medicine, Division of Medical Physics, Oregon Health & Science University, Portland, Oregon.
Theodore R HobbsOregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon.
Lauren D MartinOregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon.
Rhonda MacAllisterOregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon.
Benjamin N BimberOregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon.
Mark K SlifkaOregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon.
Alfred W LegasseOregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon.
Cassandra MoatsOregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon.
Michael K AxthelmOregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon.
Jeremy SmedleyOregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon.
Anne D LewisOregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon.
Lois ColginOregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon.
Gabrielle MeyersDivision of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon.
Richard T MaziarzDivision of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon.
Benjamin J BurwitzVaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon.
Jeffrey J StantonOregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon.
Jonah B SachaVaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon.
Oregon National Primate Research Center · USOregon Health & Science University · US

Funding

Upgrade of confocal microscopy at the Oregon National Primate Research CenterP51OD011092 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI Bonnie J. Nagel · 2012 to 2026
$203.9M
A nonhuman primate model of stem cell transplantation to understand determinants of post-transplant SIV clearanceR01AI129703 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI SACHA, JONAH B. · 2017 to 2025
$7.8M
Development of a Yellow Fever Vaccine for Vulnerable PopulationR44AI079898 · NIAID · NAJIT TECHNOLOGIES, INC. · PI AMANNA, IAN JAMES, SLIFKA, MARK K · 2011 to 2020
$6.2M
Non-canonical epitope presentation and antigen processing by MHC-ER01AI175459 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI Klaus J Fruh, Jonah B. Sacha · 2023 to 2026
$2.8M
Development of a Yellow Fever Vaccine for Vulnerable PopulationsR43AI079898 · NIAID · NAJIT TECHNOLOGIES, INC. · PI AMANNA, IAN JAMES, SLIFKA, MARK K · 2008 to 2009
$585k
Graft versus host immunity in SIV clearance following stem cell transplantation.R21AI112433 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI SACHA, JONAH B. · 2014 to 2015
$481k
Slide Scanner for the ONPRC Imaging and Morphology CoreS10OD025002 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI SRINIVASAN, SATHYA · 2018 to 2018
$146k
NIAID NIH HHS R01 AI129703NIAID NIH HHS R01 AI175459NIAID NIH HHS R21 AI112433NIAID NIH HHS R43 AI079898NIAID NIH HHS R44 AI079898NIH HHS P51 OD011092NIH HHS S10 OD025002
6 · The paper itself

Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) and xenotransplantation are accompanied by viral reactivations and virus-associated complications resulting from immune deficiency. Here, in a Mauritian cynomolgus macaque model of fully MHC-matched allogeneic HSCT, we report reactivations of cynomolgus polyomavirus, lymphocryptovirus, and cytomegalovirus, macaque viruses analogous to HSCT-associated human counterparts BK virus, Epstein-Barr virus, and human cytomegalovirus. Viral replication in recipient macaques resulted in characteristic disease manifestations observed in HSCT patients, such as polyomavirus-associated hemorrhagic cystitis and tubulointerstitial nephritis or lymphocryptovirus-associated post-transplant lymphoproliferative disorder. However, in most cases, the reconstituted immune system, alone or in combination with short-term pharmacological intervention, exerted control over viral replication, suggesting engraftment of functional donor-derived immunity. Indeed, the donor-derived reconstituted immune systems of two long-term engrafted HSCT recipient macaques responded to live attenuated yellow fever 17D vaccine (YFV 17D) indistinguishably from untransplanted controls, mounting 17D-targeted neutralizing antibody responses and clearing YFV 17D within 14 days. Together, these data demonstrate that this macaque model of allogeneic HSCT recapitulates clinical situations of opportunistic viral infections in transplant patients and provides a pre-clinical model to test novel prophylactic and therapeutic modalities.

Indexed as

Disease Models, AnimalHematopoietic Stem Cell TransplantationOpportunistic InfectionsVirus DiseasesAllograftsAnimalsHumansMacaca fasciculariscytomegalovirushematopoietic stem cell transplantationlymphocryptovirusMauritian cynomolgus macaquesnon-human primatesopportunistic infectionspolyomavirustransplant complicationsyellow fever virus

Identifiers

PMID31930750
PMCPMC7354885
OpenAlexW2999285066

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.